Original Article
Vismodegib for treatment of periocular basal cell carcinoma – 6-year experience from a tertiary cancer center
Catarina Xaviera,
, Edgar Lopesa, Catarina Bexigab, Cecília Mourac, Emanuel Gouveiab, Ana Filipa Duartea,d
Corresponding author
a Department of Ophthalmology, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal
b Department of Oncology, Instituto Português de Oncologia Francisco Gentil, Lisboa, Portugal
c Department of Dermatology, Instituto Português de Oncologia Francisco Gentil, Lisboa, Portugal
d Department of Ophthalmology, Instituto Português de Oncologia Francisco Gentil, Lisboa, Portugal
Read
6855
Timeswas read the article
2877
Total PDF
3978
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 41 | 23 | 64 |
| 2025 5 | 163 | 54 | 217 |
| 2025 4 | 173 | 47 | 220 |
| 2025 3 | 144 | 48 | 192 |
| 2025 2 | 175 | 75 | 250 |
| 2025 1 | 107 | 60 | 167 |
| 2024 12 | 93 | 55 | 148 |
| 2024 11 | 132 | 68 | 200 |
| 2024 10 | 116 | 76 | 192 |
| 2024 9 | 142 | 85 | 227 |
| 2024 8 | 139 | 112 | 251 |
| 2024 7 | 155 | 134 | 289 |
| 2024 6 | 103 | 78 | 181 |
| 2024 5 | 94 | 70 | 164 |
| 2024 4 | 101 | 92 | 193 |
| 2024 3 | 96 | 77 | 173 |
| 2024 2 | 88 | 79 | 167 |
| 2024 1 | 59 | 51 | 110 |
| 2023 12 | 65 | 52 | 117 |
| 2023 11 | 84 | 92 | 176 |
| 2023 10 | 54 | 82 | 136 |
| 2023 9 | 69 | 76 | 145 |
| 2023 8 | 59 | 35 | 94 |
| 2023 7 | 48 | 39 | 87 |
| 2023 6 | 60 | 48 | 108 |
| 2023 5 | 40 | 28 | 68 |
| 2023 4 | 35 | 15 | 50 |
| 2023 3 | 69 | 50 | 119 |
| 2023 2 | 51 | 33 | 84 |
| 2023 1 | 36 | 48 | 84 |
| 2022 12 | 51 | 38 | 89 |
| 2022 11 | 101 | 52 | 153 |
| 2022 10 | 208 | 52 | 260 |
| 2022 9 | 57 | 62 | 119 |
| 2022 8 | 46 | 52 | 98 |
| 2022 7 | 30 | 57 | 87 |
| 2022 6 | 59 | 58 | 117 |
| 2022 5 | 40 | 57 | 97 |
| 2022 4 | 45 | 55 | 100 |
| 2022 3 | 63 | 79 | 142 |
| 2022 2 | 31 | 36 | 67 |
| 2022 1 | 117 | 109 | 226 |
| 2021 12 | 166 | 113 | 279 |
| 2021 11 | 117 | 74 | 191 |
| 2021 10 | 35 | 69 | 104 |
| 2021 9 | 21 | 32 | 53 |
Show all
